and behavioral questionnaire, underwent a comprehensive cardiometabolic risk assessment (anthropometrics, blood pressure and labs), and provided blood samples for banking. Laboratory results of cardiometabolic testing were returned to the participants and their providers through the electronic health record. Results: During the first 2 years of recruitment into the SPS Biobank, 2,335 patients were approached and 1,432 (61.3%) consented to participate; 1,354 (94.5%) ultimately completed all requisite questionnaires and medical evaluations. The cohort is primarily Spanish-speaking (72.9%), female (73.3%), with a mean age of 41.3 ± 12.5 years. Most participants were born outside of the US (77.9%) and do not have health insurance (77.5%). The prevalence of overweight (35.5%) and obesity (45.0%) was high, as was previously unidentified prediabetes (55.9%), type 2 diabetes (7.4%), prehypertension (46.8%), and hypertension (16.2%). The majority of participants rated their health as good to excellent (72.1%) and, as a whole, described their overall quality of life as high (7.9/10). Conclusion: Collaborative efforts
Introduction
Biomedical research has entered a remarkable age of innovation with the emergence of high-speed, low-cost methods for sequencing human DNA. This new capacity is spurring a variety of initiatives in precision medicine focused on identifying early biomarkers of disease and designing treatment plans based on the unique biological features of individual patients [1] . Alongside these remarkable advances is the unfortunate reality that many historically underserved communities continue to struggle with an ever-widening health disparities gap, particularly with respect to advanced medical technologies [2] . If precision medicine is to realize its full potential as a tool for improving human health and reducing the burdens of disease, it will be critical to reach individuals with limited financial resources and other historically underrepresented populations that have difficulty accessing healthcare services.
Ensuring biobanks produce information that is relevant to a diverse population must be coupled with approaches that facilitate integration of precision medicine into diverse clinical practice settings [3] . As the practice of precision medicine becomes more common, it will likely extend beyond academic medical institutions and into community health centers that serve low-income and/or uninsured patients. These community health centers become increasingly important with the Affordable Care Act as they emphasize coordinated primary and preventive care for vulnerable and underserved populations through a comprehensive patient-centered medical home [4] .
Potential barriers to ensuring sociodemographic diversity in biobanks are similar to documented challenges for enrolling diverse and vulnerable populations into clinical research studies. These obstacles include disparities in access, health literacy, trust, transparency, communication, and mutual respect [5] . Clinical researchers often collaborate with community agencies and stakeholders to overcome these difficulties in enrolling diverse populations into clinical research studies [6] . Although this model may work well for recruitment into clinical trials, biobanks are somewhat unique because linking samples with the participant's medical record, preferably within their medical home where they receive regular care, is essential [7] . Therefore, new models of academiccommunity collaboration to support precision medicine through biobanking may be necessary. Ideally, these new models would include a collaborative governance structure, clearly defined protocols for handling return of results, support for ongoing contact with patients, and a platform for regular engagement and dialogue with the larger community.
The leadership from the Mayo Clinic Biobank and the Center for Individualized Medicine recognized these issues and the need for new biobanking models that can move the field of precision medicine forward. In this report, we describe the process by which the Mayo Clinic undertook a deliberate campaign to extend biobanking to an underrepresented Latino community through collaborating with Mountain Park Health Center (MPHC), a Federally Qualified Health Center that provides primary medical care and behavioral health services to low-income patients in Phoenix, Arizona. The end result is the Sangre Por Salud (Blood for Health; SPS) Biobank that is focused on recruiting and enrolling adult Latino patients from MPHC with no history of diabetes who consent to (1) specimen banking; (2) standardized cardiometabolic disease risk phenotyping; (3) completing questionnaires assessing sociodemographic characteristics, personal and family health history, lifestyle, and other behaviors (e.g. cancer prevention) and exposures (e.g. environmental toxins); (4) accessing data from their medical records, and (5) re-contacting for future studies. With this context, the aims of this paper are to (1) present select sociodemographic and clinical characteristics of the participants enrolled during the first 2 years of the SPS Biobank, and (2) identify practices and procedures that have contributed to the overall success of this unique collaboration.
Methods

Background and History
The Mayo Clinic Center for Individualized Medicine is committed to providing infrastructure for biobanking. The first biobank, the Mayo Clinic Biobank, leverages patient, physician, research, and health systems resources to support a wide array of health-related research studies and has been described in more detail elsewhere [8] . The data in the Mayo Clinic Biobank are rich in terms of health conditions and deep in terms of patient records, as more than half of the participants have more than a 15-year history of medical record data to link with results of studies using their biospecimens or other data. Despite this strength, a limitation of the Mayo Clinic Biobank is the lack of diversity in terms of race/ 231 ethnicity ( ∼ 95% report European ancestry) and indicators of socioeconomic status (e.g. >80% have at least an associates degree). Recognizing the need to enhance diversity within the Mayo Clinic Biobank in order to produce more generalizable information that could be applied to various practice settings, the Center for Individualized Medicine at the Mayo Clinic looked beyond their patient-care network to establish a new model for biobanking. This model capitalized on the successful experience and infrastructure in order to extend precision medicine research to an underrepresented Latino patient population served by a Federally Qualified Community Health Center.
Establishing the Model
Prior to developing the SPS Biobank, an established partnership was in place between Mayo Clinic and MPHC; this partnership included research as well as patient care. A master agreement between the two institutions was in place and allowed for MPHC to rely on the Mayo Clinic Institutional Review Board (IRB) as the IRB of record. MPHC leadership and the research team recognized the importance of comprehensively integrating the SPS Biobank into the MPHC practice so that a separate agreement was needed to support this collaborative endeavor. In order to further embed the SPS Biobank within the practice and ensure its success, it was decided that (1) MPHC staff would become members of the research 'core team'; (2) only active MPHC patients would be enrolled into the SPS Biobank, and (3) the project needed to bring direct benefit to MPHC and their patients. To accomplish this, sample collection for banking would occur in the context of a routine clinical blood draw ordered by MPHC providers. SPS Biobank also provided funding for selected clinical labs [complete blood count with differential, complete metabolic panel, lipid panel, hemoglobin A1c (HbA1c)] ordered during this blood draw that were not covered by the patient's insurance. These labs were decided upon collaboratively by the SPS research team and MPHC staff to provide a risk profile for cardiovascular disease and type 2 diabetes, the major health issues for this population. This was also perceived as a benefit by MPHC leadership, as their providers are often faced with the challenge of ordering medical tests that patients cannot afford. As a consequence, those orders often go unfilled and the tests are not performed. By providing funding for these tests, the SPS Biobank would gain the benefit that all participants enrolled in the biobank would receive a set of tests that would form the basis for a standardized phenotype (described below). This was intended to extend and complement the Electronic Health Record. The rationale for the focus on Latino patients was based on three points: (1) the widespread underrepresentation of Latinos in clinical research and biobank studies; (2) the predominance of Latino patients served by MPHC (>70% of active patients), and (3) the extensive experience of the research team in working with Latino participants in clinical studies.
Once the conceptual framework for integrating the SPS Biobank into MPHC's clinical flow was established, attention was turned to developing the protocol and obtaining IRB approval. The protocol needed to take into account operational logistics for (1) handling research specimens that needed to be transported by courier ∼ 30 miles each study day for processing in the Mayo Clinic Biospecimen Accessioning and Processing Core laboratory; (2) transferring clinical data from the MPHC electronic health record to a research database housed within Mayo Clinic, and (3) training and certifying MPHC personnel in the responsible conduct of research. As part of the protocol, a detailed health history form from the Mayo Clinic Biobank questionnaire was adapted and modified to include pertinent constructs and measures that are culturally and environmentally congruent with the local Latino population of Phoenix, Ariz. Adaptation of the self-administered questionnaire and selection of appropriate measures was conducted collaboratively between the institutions, with particular consideration given to the issue of available and psychometrically sound Spanish-language translations. In addition, a comprehensive family history questionnaire was developed that specifically targets common, chronic health conditions in the population, type 2 diabetes, cardiovascular disease, and cancer. It was decided that this particular instrument would be interviewer administered in order to develop the most accurate family pedigrees as possible. Overall quality of life (QoL) rating was obtained by a single question, 'How would you describe your overall quality of life?', rating 0 ('as bad as it can be') to 10 ('as good as it can be') [9] .
Recruitment and Enrollment
In order to facilitate enrollment and minimize any negative impact on clinical flow, the SPS Biobank research team and MPHC providers held several discussions to identify a recruitment strategy that would work efficiently within the MPHC internal medicine practice. The mechanism that was deemed to work most efficiently was for biobank staff to screen daily patient logs for general inclusion/exclusion criteria (e.g., age, ethnicity, health status) and alert MPHC providers and medical assistants that a patient may be eligible. During a visit, the MPHC medical providers offered potentially eligible patients a very brief overview of the biobank and asked if they wanted to learn more. Patients who expressed interest in hearing more were then referred to SPS Biobank research staff. Eligibility criteria included self-reported Latino ethnicity, age 18-85 years, and classification as an active MPHC patient with a recorded visit within 6 months of biobank enrollment. Patients were excluded if they (1) had a confirmed diagnosis of type 2 diabetes; (2) had a history of cancer in the past 3 years (excluding non-melanoma skin cancers), patients in remission >3 years were eligible; (3) were pregnant, had delivered a child in the last 12 months, or were breastfeeding within the last 3 months, or (4) were unable to abstain from smoking during the duration of the study visit ( ∼ 4 h). Patients who met these criteria and expressed interest were referred to a clinical research coordinator for a full explanation of study procedures and, if interested in participating, were scheduled for administration of informed consent. Informed consent was obtained by bilingual/bicultural research coordinators for the collection of metabolic, anthropometric, sociodemographic, and family history data, as well as 50 ml of blood for biobanking, access to their medical record, the ability to recontact in the future. Coordinators were trained by an experienced researcher with a long track record of recruiting and enrolling Latino participants into clinical research studies. Participants were provided the consent to read over, and then the study purpose, procedures, risks, benefits, and alternative approaches were explained in detail by the coordinator in the participants' preferred language. Any questions were answered prior to signing the consent. All documents were available in English and Spanish with translations approved by MPHC staff prior to submission to the IRB in order to ensure attention to the local Spanish dialect. All procedures were approved by the Mayo Clinic IRB, and a Certificate of Confidentiality from NIH was secured.
Data Collection
Participants were scheduled for the study visit in the morning after an overnight fast. Height, weight, waist circumference, seated blood pressure, pulse, and temperature (to rule out acute illness) were measured. A fasting blood draw was collected for complete blood count with differential, complete metabolic panel, lipid panel (triglycerides, total, LDL, HDL cholesterol), HbA1c, and glucose. Samples for banking were collected simultaneously with clinical samples. After fasting samples were drawn, participants consumed 75 g of glucose in solution for the oral glucose tolerance test (OGTT). An OGTT is considered the gold-standard for diagnosing type 2 diabetes and may provide additional risk stratification above and beyond fasting glucose and HbA1c [10] . Given the disproportionate rates of diabetes in the Latino community and the overrepresentation of diabetic patients in the MPHC practice, the OGTT was perceived as an added value by MPHC staff and would allow participants sufficient time to complete the family history and questionnaire. Laboratory analysis for clinical testing was performed by the commercial laboratory used by MPHC to facilitate integration of results into the electronic medical record and ensure appropriate communication and follow-up with a provider in a timely manner.
Access to the SPS Biobank Data and Specimens
Investigator access to samples (DNA, RNA, serum, plasma) or data from the SPS Biobank or re-contact participants follows a 5-step process ( fig. 1 ).
Step 1 is a written access request submitted to the SPS biobank. This step may include input from the research coordinators and/or staff from MPHC.
Step 2 is a review by the SPS Biobank Core Team (MPHC leadership and staff, along with investigators and Mayo Clinic administrators) to determine whether the request is congruent with MPHC's mission. MPHC's mission includes working with the communities it serves to sustain and improve health by providing affordable primary care. This review allows MPHC the opportunity to clarify what impact the request may have on their practice, patient populations, and/or reputation and occurs prior to reviews by the Mayo Clinic Biobank Access Committee or the IRB. Importantly, this step allows MPHC to identify requests that might be perceived to result in harm to the MPHC practice or community trust and have input on modifying such requests in a way that would mitigate risks. Investigators are provided with MPHC's mission, encouraged to visit the MPHC website, and asked to describe any benefits their project may have to MPHC and/or their patients. These benefits can include immediate, long-term, or potential benefits. In addition to gaining access to specimens and data from the SPS Biobank, this process may encourage investigators to work with MPHC on collaborative research and clinical projects that will further benefit the practice and patient population. Requests that present potentially challenging issues could be taken to a Community Advisory Board (CAB; described below) for feedback, discussion, and advice.
Step 3 is a 'screening meeting' to collect study specific details and to ensure a complete understanding of the logistics, timeline and study costs.
Step 4 is a review by the Mayo Clinic Biobank Access Committee comprised of researchers, providers, and staff from both institutions. If approved by the Access Committee, the project is submitted to the Mayo Clinic IRB for final approval (step 5). The above process mirrors the process used by the Mayo Clinic Biobank, with the additional step described in step 2 for MPHC 'mission fit' review. MPHC is involved in all 5 steps of this process.
Community Advisory Board
In parallel with establishing an access process, both the SPS research team and MPHC agreed that community input would be essential for transparency, broader engagement, shared decision making for complex ethical issues, and overall governance of the biobank. To facilitate these goals, a CAB was established through MPHC. A bilingual/bicultural CAB coordinator was hired by MPHC and charged with recruitment of members that would be comprised of MPHC patients, SPS Biobank participants, community members, and other stakeholders. CAB meetings have been held every other month at MPHC and include general research education, updates on the progress of the SPS Biobank, presentations by researchers with active SPS Biobank protocols, and opportunities for the CAB to provide feedback and advice. Case studies and real life examples are used to stimulate discussion among CAB members. CAB meetings are conducted in Spanish since many members are monolingual Spanish-speaking, with simultaneous translation provided for attendees and non-Spanish speaking presenters. Although the CAB can play a role in providing input on perceived benefits, risks, and the impact of research on the community, they serve as an advisory, not approval, board.
Statistical Analysis
Descriptive data are presented as percentages for categorical data or means ± standard deviations for continuous data. Sex differences were assessed by χ 2 and independent sample t tests or
Step 1 Submit access request: samples, data, re-contact
Step 2 MPHC 'mission fit'
Step 3 Screening meeting Logistics, timeline, budget
Step 4 Mayo Clinic Biobank access Committee approval
Step 5 IRB approval
Step 2a CAB input Fig. 1 . Approval process for accessing data, samples, and re-contact of participants in the SPS Biobank. Mission fit: the SPS Core team determines whether the access request is congruent with the mission of MPHC, and this provides MPHC the opportunity to clarify what impact the request may have on their practice, patient population, and/or reputation. CAB input: CAB input may be sought if broader community input regarding the science, ethics, or operations is warranted before initiating the project.
Wilcoxon rank sum. To describe the diversity between the SPS Biobank and the Mayo Clinic Biobank, select demographics variables (age, sex, weight status, education level, self-rated health, and QoL) were compared between the two biobank populations. To compare SPS with the Mayo Clinic Biobank, categorical variables were compared by χ 2 , while continuous variables were evaluated by independent sample t tests or Wilcoxon rank sum.
Results
During the first 2 years of enrollment, 2,335 MPHC patients met general inclusion/exclusion criteria as determined from a review their medical record. These individuals were subsequently approached and 1,432 (61.3%) consented to participate. Of those who consented, 1,354 (94.5%) were phenotyped for cardiometabolic risk, provided samples for banking, and competed the family health history as well as the sociodemographic questionnaires. One participant withdrew consent within 1 week of completing the study visit, and these data are not included in this report. Men and women in the SPS Biobank were similar in terms of BMI, age, education levels, selfrated health, and QoL ( table 1 ) . Overall, the SPS Biobank cohort is primarily Spanish-speaking (72.9%), female (73.3%), with a mean age of 41.3 ± 12.5 years. Most of the participants were born outside of the US (77.9%) and did not have health insurance (77.5%) despite varying employment status ( table 2 ). The prevalence of overweight and obesity was high (35.5 and 45.0%, respectively) as were the percentages of patients with previously unidentified prediabetes or type 2 diabetes (55.9 and 7.4%, respectively) and prehypertension or hypertension (46.8 and 16.2%, respectively). The majority of participants rated their health as good to excellent (72.1%) and, as a whole, described their overall QoL near the positive end on the Likert scale (mean QoL 7.9/10). These findings were corroborated in the relatively low prevalence of the top 10 health conditions reported in the cohort ( table 3 ) while family histories suggest that the risk for future chronic disease was likely high ( table 4 ) .
Comparison of select sociodemographic and phenotypic data between the SPS Biobank and the Mayo Clinic Biobank patients is presented in table 5 . The SPS cohort was younger (p < 0.0001), more likely to be female (p < 0.0001), had a lower proportion of lean and higher proportion of obese patients (p < 0.0001), completed less formal education (p < 0.0001), and reported lower ratings of health (p < 0.0001). The cohorts were nearly identical in terms of their reported QoL (p > 0.05).
Discussion
The SPS Biobank is an infrastructure project that was established to support precision medicine research among Latinos by (1) linking Mayo Clinic Biobank resources with a Latino-serving Federally Qualified Community Health Center, and (2) fostering research opportunities for Latino patients. The initial 2-year period supports the ability to identify, recruit, and enroll a patient population that is his- torically underrepresented in the biobanking and genomic literature [11] and is disproportionately impacted by a number of health conditions that have a genetic component [12] . As such, the SPS Biobank could serve as a model to facilitate precision medicine and genomic research in a highly vulnerable and understudied population. Data from the SPS Biobank highlight significant differences between SPS participants and those in the Mayo Clinic Biobank. One of the more striking differences between the two populations is the considerably younger age of the SPS cohort. This age difference mirrors population demographics across the US, where Latinos are the youngest population subgroup and non-Hispanic whites are the oldest [13] . The demographic landscape of the US is changing, and Latinos accounted for over 50% of the US growth rate between 2000 and 2010 [14] . Further, new immigrants and their children have been estimated to account for over 80% of US population growth between 2005 and 2050 [15] . This changing demographic landscape will likely lead to shifts in attitudes and access to health care, the types and rates of disease, as well as the genomic diversity of the US population. In anticipation of these changes, precision medicine initiatives that include sociodemographic and genomic diversity may be better able to address the health disparities gap. In order to support efforts to diversify biobanks by recruiting and enrolling vulnerable and underserved populations, we have found that a successful strategy is embed in the local health care center, hire bilingual and bicultural research staff who are familiar with the local community (important for building trust in order to capture sensitive sociodemographic data in a meaningful manner), and address an actionable health need directly relevant to the community as part of the enrollment process (here, cardiometabolic and diabetes testing). In addition to age, income and education play a major role in population-level health [16] . Approximately 50% of the Mayo Clinic Biobank cohort completed college or graduate school compared to 6% in the SPS cohort. Educational attainment is a strong protective factor against mortality in the US [17] and, in particular, among highly educated individuals [18] . While it would seem that more educated populations are universally healthier, less educated Latinos experience a longer life expectancy than non-Hispanic whites [19] . This so-called 'Latino Paradox' may offer insight into resiliency factors that could be applied to other populations to promote health and prevent disease. Although we did not directly compare income between the two cohorts, using insurance coverage as a surrogate would suggest that the SPS Biobank cohort with 77.5% uninsured patients is at an income disadvantage compared to the predominantly insured Mayo Clinic Biobank cohort. This income discrepancy is particularly relevant in the context of increasing costs for medical testing and treatment. As advances in medical technologies lead to better diagnostic procedures and individualized care, finding mechanisms to apply precision medicine to low income populations will require innovative programs that incentivize cost-effective approaches to ensure that all populations benefit from biomedical advances. Despite sociodemographic differences between SPS and Mayo Clinic Biobank participants, it is noteworthy that, as a whole, SPS participants reported self-ratings of health and QoL similar to participants in the Mayo Clinic Biobank. Self-rated health is predictive of future health outcomes [20] independent of racial and ethnic background [21] . However, the predictive value of self-rated health for future health trajectories may be partially mediated by genetic factors [22] . Therefore, integrating selfratings of health with genomic data may strengthen the predictive value of these seemingly disparate measures. With this context, biobanks that integrate various types of data (e.g., genomic, family history, behavior, sociodemographic, and perceived health, etc.) may be best situated to support prevention, early identification, and treatment models of precision medicine.
The Mayo Clinic and MPHC share a common philosophy for coordinated, patient-centered health care and have a long history of partnership. The common philosophy and track record were essential for building trust within MPHC's staff and patient population who have little exposure to academic biomedical research opportunities. Additional considerations that may further support collaborative efforts include, the integration of MPHC staff into the research team to provide input on the design, implementation, and ongoing refinement of the project, developing mutually identified goals, coordinated planning, frequent and ongoing dialogue with staff and providers not involved in the biobank, shared governance structure, and broad community input. This model of collaboration may serve as an ideal framework to leverage existing biobanking expertise and samples from large academic medical institutions to smaller institutions and community health practices that serve diverse and underrepresented populations. Collaboration may be a more cost-effective mechanism for enriching relatively homogeneous biobanks with genomic and sociodemographic diversity. To date, genomic studies have not resulted in convincing evidence that genetic differences explain racial disparities in chronic disease [23] . There are several hypotheses as to why this is the case, but a glaring limitation across these studies is the considerably larger sample size of cohorts enriched with European ancestry compared to other racial and ethnic groups [24] . Moreover, disease and disease risk phenotypes in many cases are likely to represent an interaction between genomic diversity and environmental differences. In the case of communities with health disparities such as the community from which SPS Biobank patients are drawn, contextual factors including education, health literacy, income level, and cultural beliefs are also important. Therefore, prioritizing not only genomic but also sociodemographic and cultural diversity within existing, large-scale biobanks will provide an opportunity to leverage infrastructure and capitalize on current and planned high-throughput sequencing activities that may result in more clinically relevant findings.
Another important lesson from the first 2 years of experience with the SPS collection is the importance of promoting community engagement. To sustain successful biobanks over time, both institutional and community support is critical. The complexity of biobanking and the implementation of precision medicine may be poorly understood and can create concerns, particularly among members of historically underrepresented communities [25] . Both the Mayo Clinic collection and the SPS biobank have sought to address these challenges through the creation of CABs. This priority has proven to be an essential aspect of the SPS Biobank and has contributed to increased awareness and support for biobanking research in the local communities served by MPHC. The CAB has provided advice on topics ranging from re-contacting previous participants to policies regarding withdrawal of consent. The CAB has also hosted Mayo Clinic researchers who have presented results of their work involving biobank samples, which has led to discussion of how their work may be expanded to have a greater impact in the Latino community. Although these activities have a regional focus, the hope is to share these experiences with others, highlighting potential opportunities to expand this model in other communities [26] . Efforts are also underway to coordinate CAB activities across regional biobank sites, to foster a broader sense of community, share perspectives across communities, and promote dialogue among multiple community advisors.
Strengths of the SPS Biobank include (1) the focus on an underrepresented population in biomedical research; (2) leveraging the experience and infrastructure of the Mayo Clinic Biobank; (3) embedding the biobank in a federally qualified community health center, and (4) nurturing a robust local CAB. Despite these strengths, there are limitations that are worthy of comment. First, the SPS Biobank is not intended to be representative of all Latinos nor is it representative of the local community. By design, we recruited otherwise healthy, non-pregnant Latino pa- tients, but the MPHC practice is more diverse, with a large proportion of diabetic patients as well as pregnant and postpartum women. In addition, we excluded patients below age 18 despite the fact that children make up approximately 45% of the MPHC patient population. Second, the overall sample size is relatively small compared to other diverse biobanks, but the size and pace of enrollment will increase over time. Third, despite being embedded within the patient's medical home, the richness of preexisting health information included within the medical record is likely limited as the MPHC practice only recently transitioned to an electronic medical record system. Fourth, we have not included a formal process for evaluating the collaborative project from a broader institutional or community perspective. Therefore, the ability to objectively identify key aspects for success or opportunities in need of further refinement is limited to speculation. Lastly, the purely descriptive nature of the dataset that is restricted to a subset of select clinical and sociodemographic variables is limiting. Further, since genomic sequencing is not a standard procedure within the SPS Biobank, we have included the three most prevalent and preventable diseases in the population. We acknowledge that there are limitations in the accuracy of family history data that could be minimized by enrolling family members. As future studies utilize the infrastructure created by the SPS Biobank and employ additional methodologies, interventions, or follow-up data points, these elements will be integrated to provide a more comprehensive picture of the cohort and the individual patients enrolled.
Conclusion
The SPS Biobank was created to promote diversity among participants in precision medicine research and provide opportunities for low-income Latino patients to participate in biomedical research. Efforts to foster transdisciplinary research projects and expand the SPS Biobank are underway and will likely yield unique opportunities to address health disparities in Latino communities. As these efforts materialize, the long-term success of the SPS Biobank will be fully appreciated by advancements in the field and measurable improvements in health outcomes. Although the success of the infrastructure will be measured in the future, we believe the lessons learned in developing the SPS Biobank offer implications for future work to build upon. These implications include the importance of follow-up collections, opportunities to recruit family members for an enhanced family history with more complete pedigrees, enhanced phenotyping beyond what may be in the medical record, initiation of genomic sequencing, the assessment of health and genomic literacy, the collection of relevant psychosocial and behavioral measures, and a formal evaluation of the process by which participants are enrolled and institutions collaborate to diversify precision medicine efforts.
